RAPT Therapeutics/$RAPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RAPT Therapeutics
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Ticker
$RAPT
Sector
Primary listing
Employees
61
Headquarters
Website
RAPT Metrics
BasicAdvanced
$496M
-
-$6.60
0.01
-
Price and volume
Market cap
$496M
Beta
0.01
52-week high
$42.39
52-week low
$6.88
Average daily volume
539K
Financial strength
Current ratio
13.253
Quick ratio
12.953
Long term debt to equity
0.583
Total debt to equity
1.924
Profitability
EBITDA (TTM)
-111.989
Management effectiveness
Return on assets (TTM)
-46.24%
Return on equity (TTM)
-77.83%
Valuation
Price to book
3.02
Price to tangible book (TTM)
3.02
Price to free cash flow (TTM)
-5.273
Free cash flow yield (TTM)
-18.97%
Free cash flow per share (TTM)
-5.69
Growth
Earnings per share change (TTM)
-73.60%
3-year earnings per share growth (CAGR)
-31.34%
Bulls say / Bears say
RPT904 outperformed Roche’s Xolair in a 16-week chronic spontaneous urticaria trial, showing stronger symptom improvement and higher rates of complete remission, which led to a 14.8% stock jump and suggests strong commercial potential.
As of March 31, 2025, RAPT had $179.3 million in cash and marketable securities, securing at least ten quarters of funding at current spending rates and backing the planned start of a Phase 2b study for RPT904.
On September 29, 2025, the FDA cleared RAPT’s IND application to start a Phase 2b trial of RPT904 in food allergy, reflecting regulatory approval and opening the door to a significant, underserved market.
The 1-for-8 reverse stock split effective June 16, 2025 signals ongoing share price weakness and efforts to stay Nasdaq-compliant, which points to limited investor demand.
D. E. SHAW & CO. sold 89.1% of its RAPT holdings in Q1 2025, raising concerns about institutional confidence and the company’s future.
Cash reserves dropped from $179.3 million on March 31 to $168.9 million by June 30, 2025 due to higher R&D spending, underlining a high burn rate and suggesting a possible need for future fundraising.
Data summarised monthly by Lightyear AI. Last updated on 24 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RAPT Therapeutics stock?
RAPT Therapeutics (RAPT) has a market cap of $496M as of October 24, 2025.
What is the P/E ratio for RAPT Therapeutics stock?
The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of October 24, 2025.
Does RAPT Therapeutics stock pay dividends?
No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next RAPT Therapeutics dividend payment date?
RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.
What is the beta indicator for RAPT Therapeutics?
RAPT Therapeutics (RAPT) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.